Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01407198 · ClinicalTrials.gov registry record · Phase 1
Nilotinib With Radiation for High Risk Chordoma
A Phase 1 study of Chordoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01407198 is a Phase 1 study of Chordoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01407198, a Phase 1 study of Chordoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells. During this research study, subjects will also receive radiation therapy which is considered a standard treatment for advanced chordomas. It is hoped by adding nilotinib, the benefits of radiation therapy can be enhanced without adding significant toxicities. The purpose of this research study is to determine the safety of nilotinib when used in combination with radiation therapy, and the highest dose of nilotinib that can be given safely with radiation therapy.
Conditions Studied
Interventions
- RADIATION Radiation therapy
- DRUG Nilotinib
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-08 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01407198
The ClinicalTrials.gov registry entry for NCT01407198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (73% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation therapy is the first listed.
NCT01407198 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01407198 about?
NCT01407198 is a clinical study titled "Nilotinib With Radiation for High Risk Chordoma". The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells. During this research study, subjects will also receive radiation therapy which is considered a standard treatment for advanced chordomas. It is hoped by adding nilotin...
What is the current status of trial NCT01407198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2011-08. Estimated completion is 2025-06.
What conditions does trial NCT01407198 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT01407198?
The interventions under investigation include: Radiation therapy (RADIATION), Nilotinib (DRUG).
Who is sponsoring clinical trial NCT01407198?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01407198 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
A Study of ERAS-601 in People With Chordoma
RECRUITING · Phase 1
-
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
ACTIVE NOT RECRUITING · Phase 1
-
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
COMPLETED · Phase 1
-
Children and Adults With Chordoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.